YOKNEAM, Israel, March 24, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026.
Shares of InMode Ltd. (NASDAQ: INMD - Get Free Report) have received an average rating of "Hold" from the nine ratings firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and one has assigned a buy recommendation to the
InMode Ltd. (NASDAQ: INMD - Get Free Report) gapped up prior to trading on Friday. The stock had previously closed at $12.76, but opened at $13.71. InMode shares last traded at $13.5850, with a volume of 653,419 shares changing hands. Wall Street Analysts Forecast Growth A number of research firms have recently weighed in on
YOKNEAM, Israel, March 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that its Board of Directors has authorized a new share repurchase program for up to approximately 10% of the Company's total shares outstanding, representing approximately 6.38 million ordinary shares.
InMode Ltd. (INMD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
YOKNEAM, Israel, Feb. 26, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences in March: Barclays 28th Annual Global Healthcare Conference Presenters: Yair Malca, Chief Financial Officer Format: In-person fireside chat moderated by Matt Miksic, Senior Equity Analyst, and one-on-one meetings Location: Miami, FL When: Wednesday, March 11 at 12:30 pm ET A live webcast of the presentation can be accessed here.
The committee, formed by InMode's board, evaluated multiple proposals for a potential transaction with help from outside financial and legal advisers. After reviewing the final bids, it concluded that none were adequate or in the best interests of the company and its shareholders, and decided to discontinue the process.
YOKNEAM, Israel, Feb. 23, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) a leading global provider of innovative medical technologies ("InMode" or the "Company"), today announced that the independent transaction committee of its Board of Directors (the "Committee") has completed its review of proposals received in connection with a potential transaction.
InMode Ltd. remains a Strong Buy at current levels, supported by a robust balance sheet, proprietary technology, and international growth. Green shoots include a 2.7% rise in consumables/servicing revenue and 14.5% international sales growth, offsetting possible U.S. market saturation. Management guides for flat 2026 revenue, with new product launches and expanding international footprint positioning INMD for future upside.
InMode Ltd. (INMD) Q4 2025 Earnings Call Transcript
